The CDFs for the HADS anxiety and depression scores (Figures 3a and b) indicate that 52.6% and 50.3% of exenatide BID patients and 52.9% and 48.0% of insulin patients reported no worsening in HADS anxiety and depression scores, respectively, at the 24-month visit (missing data overall: anxiety 19.6%; depression 21.5%). This evidence concerns the gene INS and major depressive disorder.